Cognitive Function Characteristics of Parkinson’s Disease with Sleep Disorders

Huang, Jing; Zhuo, Wen-Yan; Zhang, Yuhu; Sun, Hong; Huan, Chen; Zhu, Peipei; Pan, Xiao-Bo; Yang, Jianhao M.; Wang, Limin

doi:10.1155/2017/4267353

Cited by 7 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3106263] In China, this prevalence is 22.2–60.0%. [4917436465666768697071] The conversion rate from RBD to neurodegenerative diseases is 35.0–98.8%. The conversion rate from RBD to PD is 18.6–65.0%.…”

Section: Rapid Eye Movement Sleep Behavior Disordermentioning

confidence: 99%

See 1 more Smart Citation

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Liu

Wang

Zhan

et al. 2018

Chinese Medical Journal

View full text Add to dashboard Cite

Section: Rapid Eye Movement Sleep Behavior Disordermentioning

confidence: 99%

“…[123] In China, the prevalence of PD patients with sleep disturbance ranges from 47.66% to 89.10%. [456789] Sleep disturbance usually has adverse impact on the quality of life of PD patients. A possible pathogenesis of PD with sleep disturbance include thalamocortical pathway degeneration and changes of neurotransmitter systems.…”

Section: Introductionmentioning

confidence: 99%

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Liu

Wang

Zhan

et al. 2018

Chinese Medical Journal

View full text Add to dashboard Cite

“…Disordered sleep is one of the most frequent nonmotor symptoms in PD patients and has a significant negative impact on quality of life [ 2 ]. Disordered sleep affects 40–98% of PD patients worldwide and 47.66–89.10% of PD patients in China [ 3 , 4 ]. The possible pathogenesis of PD with sleep disturbance includes thalamocortical pathway degeneration and changes in neurotransmitter systems [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Features and Correlates of Poor Nighttime Sleepiness in Patients with Parkinson’s Disease

Qin

Xue

Chen

et al. 2020

Parkinson's Disease

View full text Add to dashboard Cite

Objective. The present study investigated the clinical features and correlates of poor nighttime sleepiness (PNS) in patients with Parkinson’s disease (PD). Methods. One hundred ten patients with PD (divided into PD-PNS group and PD-nPNS group) and forty-seven controls (nPD-PNS group) were enrolled in this study. Demographic information was collected. Patients were assessed according to the unified Parkinson’s disease rating scale (UPDRS) and Hoehn–Yahr (H&Y) stage scale. Patients were also evaluated according to the Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale (ESS), rapid eye movement sleep behavior disorder screening questionnaire (RBD-SQ), restless leg syndrome (RLS) diagnosis, Hamilton’s depression scale (HAMD), and Hamilton’s anxiety scale (HAMA). Results. The prevalence of PNS was 55.45% (61/110) in patients with PD. The PD-PNS group tended to have a longer duration of disease, higher UPDRS-I and UPDRS-III scores, a higher percentage of RLS patients, and higher HAMA and HAMD scores than those of the PD-nPNS group. The PD-PNS group tended to have a higher percentage of RBD and RLS patients and higher HAMA and HAMD scores than those of the nPD-PNS group. Analysis of the PSQI components and PSQI impact factors showed that the PD-PNS group had worse subjective sleep quality (χ2 = −2.267, P = 0.023), shorter sleep latency (χ2 = −2.262, P = 0.024), fewer sleep medications (χ2 = −4.170, P ≤ 0.001), worse daytime functioning (χ2 = −2.347, P = 0.019), and an even higher prevalence of increased nocturia (χ2 = 4.447, P = 0.035), nightmares (χ2 = 7.887, P = 0.005), and pain (χ2 = 9.604, P = 0.002) than those of the nPD-PNS group. Analysis also indicated that the PSQI global score positively correlated with BMI (r = 0.216, P < 0.05), H&Y stage (r = 0.223, P < 0.05), UPDRS-I (r = 0.501, P < 0.01), UPDRS-III (r = 0.425, P < 0.01), ESS (r = −0.296, P < 0.01), RBD (r = 0.227, P < 0.05), RLS (r = 0.254, P < 0.01), HAMA (r = 0.329, P < 0.01), and HAMD (r = 0.466, P < 0.01). In the final model, H&Y stage, RLS, UPDRS-III, and HAMD remained associated with the PQSI score (P ≤ 0.001, P ≤ 0.001, P = 0.049, P ≤ 0.001, respectively). Conclusions. Our data showed that PNS was common in patients with PD. H&Y stage, UPDRS-III, HAMD, and RLS were positively associated with PNS. Attention to the management of motor symptoms, RLS, and depression may be beneficial to nighttime sleep quality in patients with PD.

show abstract

“…27 PD patients with primary sleep disorders (RBD and insomnia) had significantly poorer global cognition, visuospatial and executive function in comparison to both unaffected controls and PD patients without sleep disorders. 28…”

Section: Sleep Disorders Related To Motor Symptoms In Parkinson's Diseasementioning

confidence: 99%

Sleep disturbance in movement disorders: insights, treatments and challenges

Bailey

Hubbard

Fasano

et al. 2021

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

Sleep and circadian rhythm disturbances are central features of many movement disorders, exacerbating motor and non-motor symptoms and impairing quality of life. Understanding these disturbances to sleep is clinically important and may further our understanding of the underlying movement disorder. This review evaluates the current anatomical and neurochemical understanding of normal sleep and the recognised primary sleep disorders. In addition, we undertook a systematic review of the evidence for disruption to sleep across multiple movement disorders. Rapid eye movement sleep behaviour disorder has emerged as the most reliable prodromal biomarker for the alpha synucleinopathies, including Parkinson’s disease and multiple system atrophy, often preceding motor symptom onset by several years. Abnormal sleep has also been described for many other movement disorders, but further evidence is needed to determine whether this is a primary or secondary phenotypic component of the underlying condition. Medication used in the treatment of motor symptoms also affects sleep and can aggravate or cause certain sleep disorders. Within the context of movement disorders, there is also some suggestion of a shared underlying mechanism for motor and sleep pathophysiology, with evidence implicating thalamic and brainstem structures and monoaminergic neurotransmission. This review highlights the need for an understanding of normal and abnormal sleep within the movement disorder clinic, an ability to screen for specific causes of poor sleep and to treat sleep disturbance to improve quality of life. Key sleep disorders also act as important biomarkers and have implications in diagnosis, prognosis and the development of future therapies.

show abstract

Cognitive Function Characteristics of Parkinson’s Disease with Sleep Disorders

Cited by 7 publications

References 27 publications

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease

Clinical Features and Correlates of Poor Nighttime Sleepiness in Patients with Parkinson’s Disease

Sleep disturbance in movement disorders: insights, treatments and challenges

Contact Info

Product

Resources

About